XIENCE™ V Everolimus Eluting CSS Components

MULTI-LINK VISION® Stent

MULTI-LINK VISION® Stent Delivery System

Everolimus

Fluoropolymer

CAUTION: XIENCE™ V is an investigational device. Limited by Federal (U.S.) law to investigational use only.
Drug Eluting Stents

• The benefits of DES outweigh potential risks

• All DES are not the same
  – There are differences in platforms, polymers, drugs and elution rates

• New therapies are best understood and advanced through robust pre-clinical, pre-market and post-market clinical research

• As new technologies evolve, efficacy and safety profiles improve over time
Drug Eluting Stents

- Cardiovascular Research Foundation (CRF) analysis of 9 clinical databases (Stone, Leon, Mehran, Kirtane, Pocock, Fahy): Data presented at TCT, October 2006
- Pre-specified analysis of safety and efficacy variables
- No differences were observed in death and MI out to 4 years for Cypher and Taxus, compared to BMS
Drug Eluting Stents

Pre-clinical assessment of DES:

• Acute safety is achieved via
  – Minimal vessel injury
  – Complete stent apposition
  – Thromboresistant materials

• Long term safety requires
  – Rapid re-endothelialization
  – A functional endothelial layer
  – Minimal chronic inflammation
  – No persistent fibrin
Drug Eluting Stents

Differences in platforms, polymers, drugs and elution rates

<table>
<thead>
<tr>
<th>Stent</th>
<th>Strut Thickness</th>
<th>Polymer Thickness</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYPHER®</td>
<td>140 um</td>
<td>12.6 um</td>
<td>152.6 um</td>
</tr>
<tr>
<td>TAXUS®</td>
<td>132 um</td>
<td>16 um</td>
<td>148 um</td>
</tr>
<tr>
<td>ENDEAVOR™</td>
<td>91 um</td>
<td>5.3 um</td>
<td>96.3 um</td>
</tr>
<tr>
<td>XIENCE™ V</td>
<td>81 um</td>
<td>7.6 um</td>
<td>88.6 um</td>
</tr>
</tbody>
</table>

3.0 mm diameter stents, 500x magnification

Data on file at Abbott Vascular

CAUTION: Endeavor and XIENCE™ V are investigational devices. Limited by Federal (U.S.) law to investigational use only.
14-Day Rabbit Iliac Re-endothelialization Study: Representative Photomicrographs of Competitive Stents

Photos on file at Abbott Vascular, Shown with permission from Dr. Renu Virmani

CAUTION: Endeavor and XIENCE™ V are investigational devices. Limited by Federal (U.S.) law to investigational use only.
14-Day Rabbit Iliac Re-endothelialization Study: Endothelialization of Competitive Stents

- **Over Struts**
  - CYPHER®: 7%
  - TAXUS®: 20%
  - Endeavor™: 78%
  - XIENCE V: 35%

- **Between Struts**
  - CYPHER®: 20%
  - TAXUS®: 40%
  - Endeavor™: 72%
  - XIENCE V: 74%

- **Overall Area**
  - CYPHER®: 35%
  - TAXUS®: 60%
  - Endeavor™: 81%
  - XIENCE V: 97%

Data on File at Abbott Vascular

CAUTION: Endeavor and XIENCE™ V are investigational devices. Limited by Federal (U.S.) law to investigational use only.
Drug Eluting Stents: From Pre-clinical Data to Clinical Results

• Differences in design yield different pre-clinical data and potentially different clinical results
## SPIRIT Family of Trials evaluating XIENCE™ V

<table>
<thead>
<tr>
<th>Trial</th>
<th>Phase</th>
<th>Region</th>
<th>N</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPIRIT First</td>
<td>Safety and Performance</td>
<td>Europe</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>SPIRIT II</td>
<td>Clinical Support for CE Launch</td>
<td>International</td>
<td>300</td>
<td>N = 1,380 (1,292/88) US: 80 sites Japan: 12 sites</td>
</tr>
<tr>
<td>SPIRIT III</td>
<td>US/Japan Approval</td>
<td>US</td>
<td>1,380</td>
<td>N = 1125 Randomized 3-vessel US: 50 sites</td>
</tr>
<tr>
<td>SPIRIT IV</td>
<td>US Peri-approval</td>
<td>US</td>
<td>~3,000</td>
<td>International N = ~3,000 Diabetic study N = ~300 Registry N = ~2700 OUS: 100 sites</td>
</tr>
<tr>
<td>SPIRIT V</td>
<td>OUS Post-CE Mark Approval</td>
<td>International</td>
<td>~5000</td>
<td></td>
</tr>
<tr>
<td>SPIRIT VI and beyond</td>
<td>US Post-approval</td>
<td>US</td>
<td>~5000</td>
<td></td>
</tr>
</tbody>
</table>

**CAUTION: XIENCE™ V is an investigational device. Limited by Federal (U.S.) law to investigational use only.**
In-stent Late Loss at 6 Months

SPIRIT FIRST

SPIRIT II

-% Lesions

In-Stent Late-Loss (6 Mo)

CAUTION: XIENCE™ V is an investigational device. Limited by Federal (U.S.) law to investigational use only.
SPIRIT FIRST & SPIRIT II: Stent Thrombosis

- Spirit First (2 yr F/U):
  - No Thrombosis in either XIENCE™ V or VISION Control through two years
- SPIRIT II (9 month F/U) : 1 thrombotic event in each group (XIENCE™ V 0.5% vs Taxus Express 1.3%) within 60 days
- Re-adjudication of Spirit First and Spirit II stent thrombosis data using Dublin/ARC definitions ongoing

CAUTION: XIENCE™ V is an investigational device. Limited by Federal (U.S.) law to investigational use only.
Abbott Vascular XIENCE™ V DES

In conclusion,

• Platform (ML Vision®): Market leading bare metal stent
• Pre-clinical data for XIENCE™ V demonstrated excellent endothelialization and limited chronic inflammation
• SPIRIT First and SPIRIT II have shown superior efficacy and encouraging safety data
• The SPIRIT family of clinical trials will evaluate >10,000 patients with long term (up to 5 year) follow-up